Newsroom

State of the GIST community: Life Raft Group’s patient registry demographics

As of December 31, 2010 the Life Raft Group’s Patient Registry has now accounted for 1,279 cases of GIST. The members of this registry have reported their clinical information to us as it pertains to their treatment of GIST. Of these 1,279 cases, we are here to report some key demographics that will help you understand who is a part of Life Raft Group GIST Community.

By |2019-12-26T14:31:38-05:00February 1st, 2011|News, Patient Registry|

National Organization for Rare Disorders Hosts Forum for FDA Commissioner and Patient Leaders

Food and Drug Commissioner Dr. Margaret Hamburg today conducted an unusual one-on-one dialogue with leaders of approximately 60 patient organizations at a forum hosted by the National Organization for Rare Disorders (NORD).

By |2019-12-26T14:30:48-05:00February 1st, 2011|News|

Latin American GIST Coalition, new challenges on the horizon for 2010

The year 2010 is gone, an important year for the Latin American GIST Coalition. In 2010 the Monterrey Declaration was signed during the first summit meeting of the group. The group had the privilege of meeting the LRG research team, who works on a daily basis to find the cure for GIST.

By |2019-12-26T14:29:52-05:00February 1st, 2011|News|

Masitinib Phase II Trial Reports Benefit in New GISTs

At the American Society of Clinical Oncology Gastrointestinal (GI ASCO) Symposium January 20, 2011, researchers reported progression-free and overall survival benefit in newly diagnosed advanced GIST patients in an ongoing Masitinib (AB1010) Phase II trial in France.

By |2019-12-26T14:27:42-05:00February 1st, 2011|Clinical Trials, News|

Clinical Trials update for February 2011

Bayer initiates a randomized Phase III trial of Regorafenib in GIST: On January 10, 2011 Bayer Healthcare in Berlin, Germany announced the initiation of a randomized phase III trial of Regorafenib (BAY 73-4506) for Gastrointestinal Stromal Tumor patients.

By |2019-12-26T14:26:51-05:00February 1st, 2011|Clinical Trials, News, Stivarga|

LRG responds to recent Cancer Cell coverage

Yesterday, there were a series of news stories reporting on an article published by Cooke et al inCancer Cell. Unfortunately, the coverage gave misleading information which could suggest that patients should not take Gleevec (imatinib) or Sutent (sunitinib).

By |2014-09-17T10:15:35-04:00January 19th, 2011|News|

PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients

January 6th, 2011 - By Jerry Call,  LRG Science CoordinatorThe first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open in [...]

Introducing…Alianza GIST!

The Latin American GIST Initiative now has a name...and a logo! Alianza GIST is a partnership of patient advocates representing ten Latin American countries and aims to improve the knowledge of patients and physicians, as [...]

By |2019-12-26T14:52:11-05:00December 1st, 2010|News|
Go to Top